Altria Group (NYSE:MO): A Contentious High-Yield Dividend Stock
Q2 2022 hedge fund letters, conferences and more PerspectivesThe most contentious issue with this stock is that the FDA has moved to ban Juul Labs from selling its devices and types of pods. A federal court recently blocked this ban while Juul labs are appealing. This is a problem for Altria as it currently has a 35% stake in the company worth $1.7B and is causing price compression for its stock. There are various takes someone can make about FDA's ban that can affect Altra's long-term value as an investment. The first is that the ban on Juul products has already been priced in, meaning that t...